F-18 Fluorodeoxyglucose Positron Emission Tomography/Computerised Tomography (FDG PET/CT) scans of the whole body are non-invasive, timely and have high diagnostic accuracy for giant cell arteritis (GCA) compared to temporal artery biopsy. There has been no evaluation of the feasibility and utility of FDG PET/CT as a first line diagnostic test in real world clinical practice. We aimed to clarify its clinical application. We audited consecutive patients who underwent FDG PET/CT imaging for investigation of giant cell arteritis at our institution. The patient cohort included inpatients and outpatients referred from rheumatologists, ophthalmologists and neurologists. Prior to imaging, a prospective patient-reported 10-item clinical data questionnaire was completed identifying symptoms and existing treatment. A FDG PET/CT scan was performed according to a specialised GCA protocol. Each study was co-reported by two experienced nuclear medicine specialists by vascular region and categorised as medium-to-large vessel vasculitis positive, negative or equivocal. Note was made of clinically relevant incidental findings. Additional clinical data including inflammatory markers, length of hospital stay, along with 6-month clinical diagnosis was retrospectively obtained from the treating clinician’s records. Concordance with second-line investigation including temporal artery biopsy and/or ultrasound was also assessed. From July 2019 to May 2020, 54 patients had been scanned (21 males, 33 females). The median age of the cohort is 75 years. Data on (1) the accuracy of FDG PET/CT imaging as first line investigation in suspected new onset GCA, (2) rate of equivocal imaging outcomes, (3) clinically relevant incidental findings and (4) scan anatomical distribution of FDG-uptake will be presented at the conference. This audit will provide insights into the real world feasibility and utility of FDG PET/CT imaging as a first-line investigation of GCA.